Bayer has announced promising new findings showing that finerenone, its non-steroidal mineralocorticoid receptor antagonist, significantly lowers the risk of chronic kidney disease (CKD) progression and major cardiovascular complications across a broad range of patients living with CKD. The latest results were presented during the 63rd European Renal Association (ERA) Congress.
According to data from the pooled INFINITY analysis, patients treated with finerenone experienced a 24% reduction in the risk of CKD progression, including kidney failure, compared with those receiving placebo alongside standard treatment. Importantly, the benefits were observed regardless of whether patients had diabetes, highlighting the medicine’s potential across diverse CKD populations.
The analysis also demonstrated significant improvements in cardiovascular outcomes. Researchers reported fewer serious heart-related events among patients receiving finerenone, reinforcing the growing evidence that kidney and cardiovascular health are closely interconnected and can be addressed simultaneously through targeted therapies.
In a separate Phase III study known as FIND-CKD, Bayer reported that finerenone significantly slowed the decline in kidney function among patients with non-diabetic chronic kidney disease. The study findings were presented at the ERA Congress and published simultaneously in the New England Journal of Medicine. Researchers described the results as both statistically significant and clinically meaningful.
Chronic kidney disease affects hundreds of millions of people worldwide and is associated with an increased risk of kidney failure, cardiovascular disease, hospitalization, and premature death. Despite advances in treatment, many patients continue to experience progressive kidney damage, creating a need for therapies that can better protect both renal and cardiovascular health.
Finerenone is already marketed by Bayer under the brand name Kerendia for specific CKD indications and has gained regulatory approvals in several countries. The newly presented findings could potentially support broader use of the therapy in future patient populations if confirmed through additional regulatory reviews and clinical evaluations.
The latest results strengthen the position of finerenone as an important treatment option in the evolving management of chronic kidney disease, offering hope for reducing both kidney-related complications and cardiovascular risks in a wider range of patients.
